Piprazon 1.125 Injection combines Piperacillin (1000mg), a broad-spectrum penicillin antibiotic, and Tazobactam (125mg), a beta-lactamase inhibitor. This combination is designed to combat bacterial infections, including resistant strains, by disrupting bacterial cell wall synthesis and neutralizing beta-lactamase enzymes that confer antibiotic resistance.
Piperacillin acts by inhibiting the bacterial cell wall, leading to cell death. Tazobactam enhances its efficacy by preventing the breakdown of Piperacillin by beta-lactamase enzymes, ensuring robust action against Gram-positive, Gram-negative, and anaerobic bacteria. This synergy makes Piprazon 1.125 Injection effective in treating a range of severe infections.
It is primarily indicated for managing hospital-acquired pneumonia, complicated urinary tract infections, intra-abdominal infections, sepsis, and skin and soft tissue infections. It is also effective in combating polymicrobial infections, especially in hospitalized or critically ill patients.
Piprazon 1.125 Injection is administered via intravenous infusion under medical supervision, ensuring rapid action and optimal therapeutic outcomes. The combination provides broad-spectrum coverage, making it a preferred choice for empiric therapy in serious infections.
Healthcare providers must monitor patients during treatment to assess therapeutic response and manage any potential side effects. It is crucial to complete the prescribed course to prevent resistance development.